(-0.02%) 5 468.20 points
(-0.03%) 39 099 points
(0.26%) 17 763 points
(-0.53%) $80.40
(-4.32%) $2.64
(-0.84%) $2 311.20
(-0.05%) $28.86
(2.27%) $1 008.80
(0.25%) $0.936
(0.69%) $10.68
(0.47%) $0.792
(-0.16%) $87.35
Live Chart Being Loaded With Signals
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways...
Stats | |
---|---|
Today's Volume | 101 044 |
Average Volume | 532 841 |
Market Cap | 129.89M |
EPS | $-0.230 ( Q1 | 2024-05-15 ) |
Next earnings date | ( $-0.340 ) 2024-08-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.68 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0130 (0.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-05 | Walbert Timothy P | Buy | 9 279 | Stock Option (Right to Buy) |
2024-06-05 | Seidenberg Beth C | Buy | 51 459 | Stock Option (Right to Buy) |
2024-06-05 | Parsey Merdad | Buy | 51 459 | Stock Option (Right to Buy) |
2024-06-05 | Hoelscher Paul W. | Buy | 9 279 | Stock Option (Right to Buy) |
2024-06-05 | Grammer Elizabeth A | Buy | 51 459 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-96.24 |
Last 39 transactions |
Buy: 5 086 661 | Sell: 305 517 947 |
Volume Correlation
Sagimet Biosciences Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sagimet Biosciences Inc. Correlation - Currency/Commodity
Sagimet Biosciences Inc. Financials
Annual | 2023 |
Revenue: | $2.00M |
Gross Profit: | $2.00M (100.00 %) |
EPS: | $-1.180 |
FY | 2023 |
Revenue: | $2.00M |
Gross Profit: | $2.00M (100.00 %) |
EPS: | $-1.180 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.380 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators